Mesoblast Limited (OTCMKTS:MEOBF – Get Free Report) shares traded up 11.2% on Monday . The company traded as high as $1.89 and last traded at $1.89. 1,125 shares were traded during mid-day trading, a decline of 38% from the average session volume of 1,810 shares. The stock had previously closed at $1.70.
Mesoblast Trading Up 11.2%
The company has a fifty day moving average price of $1.62 and a two-hundred day moving average price of $1.62.
Mesoblast Company Profile
Mesoblast Limited (OTCMKTS:MEOBF) is a global leader in regenerative medicine focused on the development and commercialization of innovative allogeneic cell therapies. The company’s proprietary platform harnesses mesenchymal lineage adult stem cells to address a range of inflammatory and immunological conditions. Mesoblast’s pipeline includes multiple late-stage and marketed products that target serious diseases with high unmet medical needs.
The company’s lead product, remestemcel-L (Ryvicor/Ryoncil), is under development for the treatment of steroid-refractory acute graft versus host disease in pediatric patients and has received conditional approval for certain indications in Japan.
Featured Stories
- Five stocks we like better than Mesoblast
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.
